がんCDK阻害剤の世界市場レポート 2025年

がんCDK阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で119億3,000万米ドルに成長します。予測期間中に成長が見込まれる背景には、新規薬剤に対する高い需要、標的がん治療に対する意識の高まり、死亡率と罹患率の上昇、抗がん剤の併用療法への注目の高まりなどがあります。予測期間における主な動向としては、分子生物学および遺伝学の発展、コンパニオン診断薬の開発、がん治療におけるデジタルヘルスおよび遠隔モニタリングの統合、がん治療における遠隔医療の利用、ドラッグデリバリーシステムの進歩などが挙げられます。

乳がんの罹患率の増加ががんCDK阻害剤市場の成長を牽引すると予想されます。乳がんは、乳房組織における異常細胞の制御不能な増殖を特徴とし、放置するとしこりや腫瘍を形成して他の身体部位に転移する可能性があります。乳がん患者の増加は、加齢、ライフスタイルの変化、遺伝的影響、検診の改善などの要因に関連しています。がんCDK阻害剤は、制御不能な腫瘍細胞の増殖を防ぎ、乳がんの他の治療効果を高める働きをします。米国がん協会のFacts and Figuresによると、米国における新規乳がん患者数は2023年の30万590人から2024年には31万3,510人に増加すると予測されています。その結果、乳がん患者数の増加ががんCDK阻害剤市場の成長に拍車をかけています。

がんCDK阻害剤市場の主要企業は、革新的なCDK2阻害剤の開発を進めるために戦略的パートナーシップを結ぶことが増えています。このような提携は、リソースや専門知識を共有し、市場アクセスを拡大し、新たな患者集団にリーチすることで、研究開発、イノベーション、商品化を加速させることを目的としています。このようなパートナーシップは、各組織の強みを生かし、新しい治療法の導入を加速させるために極めて重要です。例えば、2023年11月、米国のバイオテクノロジー企業であるベイジーン社は、同じく米国のバイオテクノロジー企業であるエンセム・セラピューティクス社とパートナーシップを締結しました。この提携により、両社はがん治療用の新しいCDK2阻害剤の開発に共同で取り組んでおり、ベイジーン社の専門知識とエンセム社のKinetic Ensembleプラットフォームを組み合わせることで、革新的ながん治療法の開発を推進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がんCDK阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがんCDK阻害剤市場：成長率分析
• 世界のがんCDK阻害剤市場の実績：規模と成長, 2019-2024
• 世界のがんCDK阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界がんCDK阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがんCDK阻害剤市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的CDK阻害剤
• 非選択的CDK阻害剤
• 世界のがんCDK阻害剤市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 前立腺がん
• 大腸がん
• その他のがんの種類
• 世界のがんCDK阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のがんCDK阻害剤市場選択的CDK阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• CDK4/6阻害剤
• CDK7阻害剤
• CDK9阻害剤
• 世界のがんCDK阻害剤市場非選択的CDK阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• CDK1阻害剤
• CDK2阻害剤
• CDK5阻害剤

第7章 地域別・国別分析

• 世界のがんCDK阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがんCDK阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がんCDK阻害剤市場：競合情勢
• がんCDK阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft（Bayer AG）Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Genentech Inc.（A subsidiary of Roche）
• Incyte Corporation
• Exelixis Inc.
• BeiGene Ltd.
• MEI Pharma Inc.
• Syros Pharmaceuticals Inc.
• Tiziana Life Sciences PLC
• Kronos Bio Inc.
• Cyclacel Pharmaceuticals Inc.
• Carrick Therapeutics Ltd.
• Qurient Co. Ltd.
• BioTheryX Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がんCDK阻害剤市場2029：新たな機会を提供する国
• がんCDK阻害剤市場2029：新たな機会を提供するセグメント
• がんCDK阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer CDK inhibitors are a class of drugs that target cyclin-dependent kinases (CDKs), which are enzymes responsible for regulating the cell cycle. CDKs play a critical role in controlling the progression of cells through various stages of division and growth. In cancer, these enzymes are often overactive, leading to uncontrolled cell division and tumor growth. Cancer CDK inhibitors are designed to interrupt this process, slowing or halting tumor growth.

The main drug types for cancer CDK inhibitors include selective CDK inhibitors and non-selective CDK inhibitors. Selective CDK inhibitors are designed to specifically target certain cyclin-dependent kinases that regulate the cell cycle in cancer cells, enhancing treatment effectiveness while minimizing side effects. CDK inhibitors are used to treat a variety of cancers, including breast cancer, lung cancer, prostate cancer, colorectal cancer, and others. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The cancer CDK inhibitors market research report is one of a series of new reports from The Business Research Company that provides cancer CDK inhibitors market statistics, including the cancer CDK inhibitors industry global market size, regional shares, competitors with the cancer CDK inhibitors market share, detailed cancer CDK inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer CDK inhibitors industry. This cancer CDK inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer CDK inhibitors market size has grown strongly in recent years. It will grow from $9.27 billion in 2024 to $9.78 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historical period can be attributed to the rising incidence of cancer, increased investment in research and development, growing awareness of personalized medicine, expansion of healthcare infrastructure, and increasing demand for innovative cancer therapies.

The cancer CDK inhibitors market size is expected to see strong growth in the next few years. It will grow to $11.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The expected growth in the forecast period is driven by a high demand for novel drugs, growing awareness of targeted cancer therapies, rising mortality and morbidity rates, and a greater focus on cancer drug combinations. Key trends in the forecast period include advancements in molecular biology and genetics, the development of companion diagnostics, the integration of digital health and remote monitoring in oncology, the use of telemedicine in cancer care, and advancements in drug delivery systems.

The increasing incidence of breast cancer is expected to drive the growth of the cancer CDK inhibitors market. Breast cancer is characterized by the uncontrolled growth of abnormal cells in the breast tissue, which can form lumps or tumors and spread to other body parts if left untreated. The rise in breast cancer cases is linked to factors such as aging, lifestyle changes, genetic influences, and improved screening. Cancer CDK inhibitors work by preventing uncontrolled tumor cell proliferation and enhancing the effectiveness of other treatments for breast cancer. According to the American Cancer Society's Facts and Figures, the number of new breast cancer cases in the United States is projected to increase from 300,590 in 2023 to 313,510 in 2024. As a result, the growing number of breast cancer cases is fueling the growth of the cancer CDK inhibitors market.

Major players in the cancer CDK inhibitors market are increasingly forming strategic partnerships to advance the development of innovative CDK2 inhibitors. These collaborations are designed to speed up research, development, innovation, and commercialization by pooling resources and expertise, expanding market access, and reaching new patient populations. Such partnerships are crucial for accelerating the introduction of new therapies by leveraging the strengths of each organization. For example, in November 2023, BeiGene Ltd., a U.S.-based biotechnology company, entered into a partnership with Ensem Therapeutics Inc., another U.S.-based biotech firm. Through this collaboration, the two companies are working together to develop a new CDK2 inhibitor for cancer treatment, combining BeiGene's expertise with Ensem's Kinetic Ensemble platform to drive the development of innovative oncology therapies.

In October 2024, Genentech Inc., a U.S.-based biotechnology company, acquired a portfolio of cyclin-dependent kinase (CDK) inhibitors from Regor Pharmaceuticals for approximately $850 million. With this acquisition, Genentech seeks to enhance its oncology pipeline by obtaining Regor Pharmaceuticals' CDK inhibitor portfolio, which includes promising candidates for breast cancer treatment. Regor Pharmaceuticals, based in China, is focused on developing targeted cancer therapies, particularly through the use of CDK inhibitors.

Major players in the cancer cdk inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer Aktiengesellschaft (Bayer AG), AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Genentech Inc. (A subsidiary of Roche), Incyte Corporation, Exelixis Inc., BeiGene Ltd., MEI Pharma Inc., Syros Pharmaceuticals Inc., Tiziana Life Sciences PLC, Kronos Bio Inc., Cyclacel Pharmaceuticals Inc., Carrick Therapeutics Ltd., Qurient Co. Ltd., BioTheryX Inc.

North America was the largest region in the cancer CDK inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer CDK inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer CDK inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer CDK inhibitors market consists of sales of palbociclib, ribociclib, and abemaciclib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer CDK Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer cdk inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer cdk inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer cdk inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Selective CDK Inhibitors; Non-Selective CDK Inhibitors
• 2) By Cancer Type: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer; Other Cancer Types
• 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Selective CDK Inhibitors: CDK4/6 Inhibitors; CDK7 Inhibitors; CDK9 Inhibitors
• 2) By Non-Selective CDK Inhibitors: CDK1 Inhibitors; CDK2 Inhibitors; CDK5 Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer Aktiengesellschaft (Bayer AG); AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer CDK Inhibitors Market Characteristics

3. Cancer CDK Inhibitors Market Trends And Strategies

4. Cancer CDK Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cancer CDK Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer CDK Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer CDK Inhibitors Market Growth Rate Analysis
• 5.4. Global Cancer CDK Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer CDK Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer CDK Inhibitors Total Addressable Market (TAM)

6. Cancer CDK Inhibitors Market Segmentation

• 6.1. Global Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective CDK Inhibitors
• Non-Selective CDK Inhibitors
• 6.2. Global Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancer Types
• 6.3. Global Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Cancer CDK Inhibitors Market, Sub-Segmentation Of Selective CDK Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CDK4/6 Inhibitors
• CDK7 Inhibitors
• CDK9 Inhibitors
• 6.5. Global Cancer CDK Inhibitors Market, Sub-Segmentation Of Non-Selective CDK Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CDK1 Inhibitors
• CDK2 Inhibitors
• CDK5 Inhibitors

7. Cancer CDK Inhibitors Market Regional And Country Analysis

• 7.1. Global Cancer CDK Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer CDK Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer CDK Inhibitors Market

• 8.1. Asia-Pacific Cancer CDK Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer CDK Inhibitors Market

• 9.1. China Cancer CDK Inhibitors Market Overview
• 9.2. China Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer CDK Inhibitors Market

• 10.1. India Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer CDK Inhibitors Market

• 11.1. Japan Cancer CDK Inhibitors Market Overview
• 11.2. Japan Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer CDK Inhibitors Market

• 12.1. Australia Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer CDK Inhibitors Market

• 13.1. Indonesia Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer CDK Inhibitors Market

• 14.1. South Korea Cancer CDK Inhibitors Market Overview
• 14.2. South Korea Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer CDK Inhibitors Market

• 15.1. Western Europe Cancer CDK Inhibitors Market Overview
• 15.2. Western Europe Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer CDK Inhibitors Market

• 16.1. UK Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer CDK Inhibitors Market

• 17.1. Germany Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer CDK Inhibitors Market

• 18.1. France Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer CDK Inhibitors Market

• 19.1. Italy Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer CDK Inhibitors Market

• 20.1. Spain Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer CDK Inhibitors Market

• 21.1. Eastern Europe Cancer CDK Inhibitors Market Overview
• 21.2. Eastern Europe Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer CDK Inhibitors Market

• 22.1. Russia Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer CDK Inhibitors Market

• 23.1. North America Cancer CDK Inhibitors Market Overview
• 23.2. North America Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer CDK Inhibitors Market

• 24.1. USA Cancer CDK Inhibitors Market Overview
• 24.2. USA Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer CDK Inhibitors Market

• 25.1. Canada Cancer CDK Inhibitors Market Overview
• 25.2. Canada Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer CDK Inhibitors Market

• 26.1. South America Cancer CDK Inhibitors Market Overview
• 26.2. South America Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer CDK Inhibitors Market

• 27.1. Brazil Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer CDK Inhibitors Market

• 28.1. Middle East Cancer CDK Inhibitors Market Overview
• 28.2. Middle East Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer CDK Inhibitors Market

• 29.1. Africa Cancer CDK Inhibitors Market Overview
• 29.2. Africa Cancer CDK Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer CDK Inhibitors Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer CDK Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer CDK Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Cancer CDK Inhibitors Market Competitive Landscape
• 30.2. Cancer CDK Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft (Bayer AG) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Cancer CDK Inhibitors Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Genentech Inc. (A subsidiary of Roche)
• 31.5. Incyte Corporation
• 31.6. Exelixis Inc.
• 31.7. BeiGene Ltd.
• 31.8. MEI Pharma Inc.
• 31.9. Syros Pharmaceuticals Inc.
• 31.10. Tiziana Life Sciences PLC
• 31.11. Kronos Bio Inc.
• 31.12. Cyclacel Pharmaceuticals Inc.
• 31.13. Carrick Therapeutics Ltd.
• 31.14. Qurient Co. Ltd.
• 31.15. BioTheryX Inc.

32. Global Cancer CDK Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer CDK Inhibitors Market

34. Recent Developments In The Cancer CDK Inhibitors Market

35. Cancer CDK Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Cancer CDK Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer CDK Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer CDK Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer